Quantcast
Home > Quotes > RYTM

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Quote & Summary Data

RYTM 
$27.58
*  
0.34
1.25%
Get RYTM Alerts
*Delayed - data as of Dec. 10, 2018  -  Find a broker to begin trading RYTM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    RYTM Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 27.745 / $ 26.27
Share Volume
120,516
50 Day Avg. Daily Volume
136,762
Previous Close
$ 27.24
52 Week High / Low
$ 37.23 / $ 16.80
Market Cap
949,047,796
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
120,516
50 Day Avg. Daily Volume:
136,762

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.05

Trading Range

The current last sale of $27.58 is 64.17% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 27.745 $ 37.23
 Low: $ 26.27 $ 16.80

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life­threatening metabolic disorders. Our lead peptide product candidate is setmelanotide, a potent, first­in­class melanocortin­4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. We believe setmelanotide, for which we have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin­4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity.  ... More ...  


Risk Grade

Where does RYTM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 27.10
Open Date:
Dec. 10, 2018
Close Price:
$ 27.58
Close Date:
Dec. 10, 2018

Consensus Recommendation

Analyst Info